Lives unaffected by cystic fibrosis

DRUG DEVELOPMENT PIPELINE

Back to the Drug Development Pipeline

Lonodelestat (formerly POL6014)

Phase One

Phase One

Therapeutic Approach

Anti-Inflammatory

This program is studying a compound designed to block the function of neutrophil elastase. Neutrophil elastase is a type of protein associated with inflammation in the lungs. Blocking the function of neutrophil elastase may minimise tissue destruction and decrease inflammation within the CF airway. 

Status

Phase 1 studies to test the safety of this compound are underway in Europe. 

Sponsor

This program is sponsored by Santhera. 



Contact us about Lonodelestat (formerly POL6014) >